Research Advance on Parkinson’s Disease Cell Model

doi:10.3969/j.issn.1674-5817.2013.01.017

Abstract

Abstract: Parkinson’s disease, which serious endangers the health of middle- aged and elderly pepole, has attracted more and more attention in these years. In the study of Parkinson‘s disease, the in vivo experiments will spend more time and money. Because of that, a lot of in vitro models have been used to reflect the pathological changes and the efficacy of new drug. Many reagents have their own specialities, and different cell lines also have their own characters, and their cell model will finally influenced the research outcome.

Key words: Parkinson's disease, Cell model, MPP⁺, Rotenone, SH-SY5Y

CLC Number:

R285.5Q95-33

FAN Zhen-qun, LIU Shu-min, ZHOU Shi-hui, WANG Ke-xin. Research Advance on Parkinson’s Disease Cell Model[J]. Laboratory Animal and Comparative Medicine, 2013, 33(1): 74-78.

References

[1] Siderowf A, Stern M.Update on Parkinson’s Disease[J]. Ann Intern Med , 2003, 138(8):651-658.
[2] Langston JW, Ballard P, Tetrud JW, et al.Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis[J]. Science, 1983, 219:979-980.
[3] Yasuhiro I,Yoshihisa K, Yasyuki N.Biphasic effects of MPP+,a possible parkinsonism inducer, on dopamine content and tyrosine hydroxylase mRNA expression in pc12 cell[J]. Neurochem Int, 1995, 26:165-171.
[4] Lee ES, Chen H, Charlton CG, et al.The Role of Phospholipid Methylation in 1-Methyl-4-Phenyl-Pyridinium Ion (MPP+)-Induced Neurotoxicity in PC12 Cells[J]. Neuro Toxicology, 2005. 26:945-957.
[5] 郑刚, 孟姗姗, 王基野, 等. MPP+对PC12细胞增殖与凋亡的影响[C]. 中国毒理会第五次全国大会论文集, 2009.
[6] Dranka BP, Zielonka J, Kanthasamy AG, et al.Bioenergetic Remodeling Induced by 1-methyl 4-phenylpyridinium (MPP+) in Dopaminergic N27 cells: Implications for Parkinson’s Disease[J]. Free Radical Biol Med, 2010, 49:154-155.
[ 7] Kook YH, Ka M, Um M. Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP+) model of Parkinson’s disease[J]. Biochem Biophys Res Commun, 2011, 411(2):370-374.
[8] 刘扬, 赵咏梅. 6-羟多巴胺诱导帕金森病动物模型的分子作用机制研究进展[J]. 中国老年学杂志, 2005, 25(12):1568-1570.
[9] Wang WJ, Song N, Zhang HY, et al.6-Hydroxydopamine upregulates iron regulatory protein 1 by activating certain protein kinase C isoforms in the dopaminergic MES23.5 cell line[J].Int J Biochem Cell B, 2012, 44(11):1987-1992.
[10] Jameson GNL, Linert W.Iron release from horse-spleen ferritin by 6-hydroxydopamine: a kinetic study[J].J Inorg Biochem, 1997, 67(14): 164.
[11] Blum D, Torch S, Nissou MF.Extracellular toxicity of 6-hydroxydopam-ine on PC12[J]. Neurosci Lett, 2000, 283: 193-196.
[12] GlinkaY, Tipton KF, Youdim MB. Mechanism of inhibition ofmito-chondrial respiratory complex I by 6-hydroxydopamine and itsprevention by desferrioxamine[J]. Eur J Pharmaco, 1998, 351(1): 121-129.
[13] Schapira AH.Mitochondrial involvement in Parkinson’s disease, Huntingtons’ disease, hereditary spastic paraplegia and Friedreich’s ataxia[J].Biochim BiophysActa, 1999,1410(2): 159-170.
[14] Lotharius J, Dugan LL, OM’ alley KL.Distinctmechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons[J]. J Neurosci, 1999, 19(4):1284-1293.
[15] Floor E, Wetzel MG.Increased protein oxidation in human sub-stantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay[J]. Neurochem, 1998, 70(1):268-275.
[16] Li NY, Ragheb K, Lawler G, et al.Mitochondrial ComplexⅠInhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen Species Production[J]. J Biol Chem, 2003, 278(10):8516-8525.
[17] Krishnan S,Chi EY,Wood SJ,et a1.Oxidative dimer formation is the critical rate-limiting step for Parkinsen’s disease 〈-synuelein fibrillogenesis[J]. Biochemistry, 2003, 42(3):829-837.
[18] Meulener M,Whitworth AJ,Armstrong-Grid CE, et al.Drosephila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson’s disease[J].Curr Biol, 2005, 15(17):1572-1577.
[19] Betarbet R, Caner-Aviles RM, Sherer TB, et al. Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, 〈-synuclein and the ubiquit in-proteasome system[J]. Neurobiol Dis, 2006, 22(2):404-420.
[20] Wang C, Ko HS, Thomas B, et al.Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function[J]. Hum Mol Genet, 2005, 14(24):3885-3897.
[21] Feng J.Microtubule: a common target for parkin and Parkinson’s disease toxins[J]. Neuroscientist, 2006, 12(6):469-476.
[22] Hoglinger GU,Carrard G, Michel PP, et al.Dysfunction of mitochondrial complexⅠand the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease[J]. Neurochem, 2003, 86(5):1297-1307.
[23] Hoglinger GU, Lannuzel A,Khondiker ME, et al.The mitochondrial complexⅠinhibitor rotenone triggers a cerebral tauopathy[J].Neurochem, 2005, 95(4):930-939.
[24] 杨咏梅. 鱼藤酮对多巴胺能神经元的损伤作用及机制[J].国际病理科学与临床杂志, 2007, 27(2): 145-148.
[25] He Y, Imam SZ, Dong Z, et al.Role of nitric oxide in rotenoneinduced nigro-striatal injury[J]. Neurochem, 2003,86(6):1338-1345.
[26] Caudle WM, Kitsou E, Li J, et al.A role for a novel protein,nucleolin,in Parkinson’s disease[J]. Neurosci Lett, 2009, 459(1):11-15.
[27] Sullivan PG, Dragicevic NB, Deng JH, et al.Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnove r[J]. J BiolChem, 2004, 279(20):20699-20707.
[28] 张海娜, 陈秋惠, 韩艳秋, 等. 蛋白酶体抑制剂制备帕金森病模型的研究进展[J]. 山东医药, 2008, 48(37):107-109.
[29] Li XP, Du YL, Fan XL, et al.c-Jun N-Terminal Kinase Mediates Lactacystin-Induced Dopamine Neuron Degeneration[J]. J Neuropath Exp Neur, 2008, 67(10): 933-944.
[30] 张振涛, 曹学兵, 孙圣刚, 等. 蛋白酶体抑制剂诱导多巴胺能神经元重启细胞周期的作用及机制[J]. 卒中与神经疾病, 2006, 13(3):134-137.
[31] 李雁, 殷娟娟, 李昕, 等. 〈-突触核蛋白寡聚体对多巴胺能神经细胞线粒体膜电位的影响[J]. 中国现代神经疾病杂,2008, 8(1):26-31.
[32] 张晨, 李昕, 李尧华, 等. 细胞外〈-突触核蛋白对MES23.5多巴胺能神经细胞的促增殖作用[J]. 首都医科大学学报,2006, 27(5):616-619.
[33] Stefanis L, Larsen KE, Rideout HJ, et al.Expression of A53T Mutant But Not Wild-Type 〈-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death[J]. J Neurosci, 2001, 12(24):9549-9560.
[34] Mosharov EV, Staal R, Bove J, et al.α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration[J]. J Neurosci, 2006, 26(36):9304-9311.
[35] 鲁玲玲, 梁源, 段春礼, 等. α-synuclein对小剂量鱼藤酮导致的线粒体损伤的调控作用研究[J]. 中国生物工程杂志,2007, 27(12):6-10.
[36] Choong CJ, Say YH.Neuroprotection of 〈-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson’s disease mutations A30P, A53T and E46K[J]. NeuroToxicology. 2011, 32(6):857-863.
[37] Shafer TJ, Atchison WD.Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies[J]. Neurotoxicology, 1991, 12(3):473-492.
[38] Ciccarone V, Spengler BA, Meyers MB, et al.Phenotypic diversification in human neruoblastoma cell: expression of distinct neural crest lineages[J]. Cancer Res, 1989, 49(1):219-225.
[39] Shan J, Todorovic M, Wood SA, et al. Parkinson disease derived hons cells are more sensitive to rotenone toxicity than control cells[J]. Parkinsonism Relat D, 2012, 18(2):192.
[40] 于鸿, 李尧华, 秀丽, 等. MES23.5细胞酪氨酸羟化酶的种属来源及其重组酶的活性测定[J] . 中国生物化学与分子生物学学报, 2004, 20(1):95-100.
[41] Jia W, Xu H, Jiang H, et al.The role of ndfip1 in iron-induced cell damage in MES23.5 dopaminergic cells[J]. Parkinsonism Relat D. 2012, 18(2):196.
[42] 张梅英, 蔺美娜, 杨葳, 等. 转染DJ-1和DJ-1^L166p基因的NIH3T3细胞中tau基因表达的研究. 实验动物与比较医学, 2008, 28(6):361-366.
[43] 韩俊燕, 张晨, 温玫, 等. α-突触核蛋白对MES23.5多巴胺能神经细胞的促增殖作用[J].中国临床康复, 2006, 10(10):104-106.
[44] Sung JY, Kim J, Paik SR, et al.Induction of neuronal cell death by Rab5A-dependent endocytosiso of alpha-synuclein[J]. J Biol Chem, 2001, 276(29):27441-27448.
[45] Fagerstrom S, Pahlman S, Gestblom C, et al.Protein kinase C-espilon is implicated in neurite outgrowth in differentiating human neuroblastoma cells[J]. Cell Growth Differ, 1996, 7(6):775-785.
[46] Fernanda L, Rafael S, Mario J, et al.Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies[J]. Brain Research, 2010,1337:85-94.